Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Children with history of diabetic ketoacidosis may have memory problems

Children who have had an episode of diabetic ketoacidosis, a common complication of diabetes, may have persistent memory problems, according to a new study from researchers at the UC Davis Center for Mind and Brain.

19 Oct 2009

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.

19 Oct 2009

Innovative tool for providing patient-centered care for diabetics

Mayo Clinic clinicians and designers, along with colleagues from other institutions, have developed and tested a tool to involve patients more in their diabetes treatment and medication choices.

19 Oct 2009

NFL, NDC launch 'Fuel Up to Play 60' to tackle childhood obesity

The NFL and National Dairy Council (NDC) today launch Fuel Up to Play 60, a new initiative aimed at tackling childhood obesity by giving youth a voice in changing the school nutrition and physical activity environment. The program will reach 36 million youth in 60,000 elementary, middle and high schools during the 2009/2010 school year.

15 Oct 2009

Resveratrol in red grapes offers some protection against diabetes

A naturally produced molecule called resveratrol, found in the skin of red grapes, has been shown to lower insulin levels in mice when injected directly into the brain, even when the animals ate a high-fat diet.

15 Oct 2009

"A Stroke of Health" for the weight loss benefits of healthy eating

Friday the 13th in June 2008 started out as a normal day for Bob and Judi Swartz, but the day would end as anything but ordinary. Bob would suffer a serious stroke and Judi would take the first steps in a year-long journey of recovery and discovery.

15 Oct 2009

National Institutes of Health grants $12 million to WCDRC for obesity research

The Miriam Hospital's Weight Control and Diabetes Research Center (WCDRC) recently received six research grants from the National Institutes of Health - totaling more than $12 million in funding - that will support the work of researchers focused on the prevention and treatment of obesity.

15 Oct 2009

Researchers to study gastric banding procedure on overweight, type 2 diabetic patients

In the first trial of its kind in the world, researchers at Monash University's Centre for Obesity Research and Education (CORE) will examine the benefits of a gastric banding procedure on overweight people with Type 2 diabetes.

15 Oct 2009

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone.

15 Oct 2009

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Metabolic Solutions Development Company (MSDC) announced today that it has received a $100,000 grant from the Alzheimer's Drug Discovery Foundation (ADDF) to support the evaluation of PPAR-sparing insulin sensitizers as a potential treatment for Alzheimer's disease.

14 Oct 2009

Positive results from Metabolex' Phase 1 MBX-2982 clinical trial for treating type 2 diabetes

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from two multiple ascending dose Phase 1 clinical trials of MBX-2982.

14 Oct 2009

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Merck Frosst Canada Ltd. announced today that its new diabetes treatment, JANUMET(TM) (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada.

13 Oct 2009

AHA: Americans should reduce their calorie intake to combat obesity and cardiovascular disease

Reaching for that chocolate chip cookie? Think twice. The American Heart Association (AHA) just released the strictest guidelines ever for added sugars, recommending Americans limit their diet to 100 calories (6 teaspoons) for women and 150 calories (nine teaspoons) for men each day.

13 Oct 2009

Neighborhood may be a modifiable risk factor for diabetes

Individuals living in neighborhoods conducive to physical activity and providing access to healthy foods may have a lower risk of developing type 2 diabetes in a five-year period, according to a report in the October 12 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

13 Oct 2009

Arena Pharmaceuticals to present Phase 3 BLOSSOM trial results at Obesity 2009

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that lorcaserin will be featured in multiple presentations at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society in Washington, DC.

12 Oct 2009

Rice consumption improves overall diet and reduces obesity and Type II diabetes

According to recent research published in the October issue of the Journal of the American Dietetic Association (JADA), eating rice helps improve overall diet and potentially reduces the risk for many chronic diseases, including obesity, cardiovascular disease and Type II diabetes.

12 Oct 2009

Santarus and Norgine enter into a licensing agreement for ZEGERID products

Santarus, Inc., a specialty biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, today announced that they have entered into a licensing agreement granting exclusive rights to Norgine to develop, manufacture and commercialize prescription immediate-release ZEGERID® products incorporating the proton pump inhibitor omeprazole in combination with one or more buffering agents in specified markets in Western, Central and Eastern Europe.

12 Oct 2009

NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, today announced successful completion of the first phase I trial with its anti-inflammatory Spiegelmer® NOX-E36. This drug candidate will be developed for the treatment of complications of type 2 diabetes, preferentially diabetic nephropathy, but also others.

12 Oct 2009

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

According to new research from the Monell Center and the Mount Sinai School of Medicine, certain common herbicides and lipid-lowering fibrate drugs act in humans to block T1R3, a nutrient-sensing taste receptor also present in intestine and pancreas.

12 Oct 2009

Study shows the impact of blood cell development on human diseases

A new genome-wide association study published today in Nature Genetics begins to uncover the basis of genetic variations in eight blood measurements and the impact those variants can have on common human diseases. Blood measurements, including the number and volume of cells in the blood, are routinely used to diagnose a wide range of disorders, including anaemia, infection and blood cell cancers.

12 Oct 2009